Tumour response, correlates of survival and clinical benefit (Nature Clinical Practice Oncology)

We are all familiar with the metrics of tumour shrinkage and time to the development of disease progression as important end points in clinical trials. This tenet is based on findings of numerous studies over several decades that have demonstrated a link between agents that